Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics

Respiratory Medicine

Volumn 93, Issue 12, 1999, Pages 863-868

  Nielsen, L P ^a   Pedersen, B ^a   Faurschou, P ^b   Madsen, F ^c   Wilcke, J T R ^d   Dahl, R ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c FREDERIKSBERG HOSPITAL   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; PLACEBO; SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DETERIORATION; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL ACCEPTABLE DOSE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033451025     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(99)90051-3     Document Type: Article

References (26)

1. The British guidelines on asthma. Thorax 1997; 52: S1-S21.
2. Asthma management and prevention. A practical guide for health officials and health care professionals. US Dept of Health and Human Services National Institutes of Health, 1995.
3. Ullman A, Svedmyr N. Salmeterol, a new long acting inhaled beta2-adrenoceptor agonist: a comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43: 674-678.
4. Dahl R, Earnshaw JS, Palmer JBD. Salmeterol: a four-week study of long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4: 1178-1184.
5. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J 1992; 5: 1062-1067.
6. Pearlman DS, Chervinsky P, LaForce C, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med 1992; 327: 1420-1425.
7. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
8. Woolcock A, Lundback B, Ringdal N, Jacques LA. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153: 1481-1488.
9. American Thorax Society. Medical section of the American lung association. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987; 136: 225-243.
10. van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting beta agonist formoterol as asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian formoterol study investigators. Thorax 1997; 52: 535-539.
11. Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK study group. Eur Respir J 1995; 8: 1494-1498.
12. Gibson PG, Wong BJO, Hepperle MJE, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992; 22: 525-532.
13. Wilding P, Clark M, Thompson-Coon J, et al. Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. Br Med J 1997; 314: 1441-1446.
14. Twentyman OP, Finnerty JP, Harris A, Palmer J, Holgate ST. Protection against allergen-induced asthma by salmeterol. Lancet 1990; 336: 1338-1342.
15. Barnes PJ, Pedersen S. Efficacy and safety of inhaled steroids in asthma. Am Rev Respir Dis 1993; 148: S1-S26.
16. Lipworth BJ. New perspectives in drug delivery and systemic bioactivity. Thorax 1995; 50: 105-110.
17. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J allergy Clin Immunol 1995; 96: 571-579.
18. Selroos O, Backman R, Forsen KO, et al. Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered-dose inhalers and Turbuhaler. Allergy 1994; 49: 888-890.
19. Wilding PJ, Clark MM, Oborne J, Bennett JA, Tattersfield AE. Effect of regular terbutaline on the airway response to inhaled budesonide. Thorax 1996; 51: 989-992.
20. Lai CK, Chan CH, Ho SS, Hui AC, Lai KN. Inhaled salmeterol and labuterol in asthmatic patients receiving high-dose inhaled corticosteroids. Chest 1995; 108: 36-40.
21. Lotvall J, Lunde H, Ullman A, Tornqvist H, Svedmyr N. Twelve months treatment with inhaled salmeterol in asthmatic patients. Effects on beta-2 receptor function and inflammatory cells. Allergy 1992; 47: 477-483.
22. Butcher PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung. Br J Pharmacol 1991; 104: 672-676.
23. Linden M. The effects of beta 2-adrenoceptor agonists and corticosteroid, budesonide, on the secretion of inflammatory mediators from monocytes. Br J Pharmacol 1992; 107: 156-160.
24. Gardiner PV, Ward C, Booth H, Allison A, Hendrick DJ, Walters EH. Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. Am J Respir Crit Care Med 1994; 150: 1006-1011.
25. Hjemdahl P, Zetterlund A, Larsson K. Beta 2-agonist treatment reduces beta 2-sensitivity in alveolar macrophages despite corticosteroid treatment. Am J Respir Crit Care Med 1996; 153: 576-581.
26. Tan KS, Grove A, McLean A, Gnosspelius Y, Hall IP, Lipworth BJ. Systemic corticosteroid rapidly reverses bronchodilator subsenstivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997; 156: 28-35.